Health care innovation: good and bad
John Goodman of the National Center for Policy Analysis has an excellent column abut health care innovation. He summarizes: Wherever there is third-party payment [insurance, a health plan, Medicare, Medicaid], the goal of innovation is to produce more products that qualify for reimbursement, even if the effects on patient outcomes are only marginal. Wherever there […]
FDA on your DNA: “You can’t handle the truth!”
From Paul Hsieh:
Recent advances in biotechnology have allowed private companies to offer affordable genetic testing directly to consumers, to help them determine their risks of developing problems such as diabetes, heart disease, and various forms of cancer. In response, the U.S. government has told these companies that their tests must be […]
